Lunai Bioworks Inc.(LNAI)Earnings, Financials & Key Ratios
LNAI•NASDAQ
Price updated Jun 19, 2026
AboutA company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.Show more
- Revenue$0
- EBITDA-$18M+77.4%
- Net Income-$178M-101.3%
- EPS (Diluted)-86.24-18.5%
- ROE-321.81%-224.8%
LNAI Key Insights
Lunai Bioworks Inc. (LNAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 69.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LNAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LNAI Price & Volume
Lunai Bioworks Inc. (LNAI) stock price & volume — 10-year historical chart
Loading chart...
LNAI Growth Metrics
Lunai Bioworks Inc. (LNAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8.32%
Return on Capital
10 Years-57.01%
5 Years-57.01%
3 Years-61.76%
Last Year-33.15%
LNAI Recent Earnings
Lunai Bioworks Inc. (LNAI) EPS & revenue vs analyst estimates — last 3 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.10
—
Rev
$20,942
—
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.08
—
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.13
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.10 | $20,942 |
| Q1 2026 | Feb 17, 2026 | $0.08 | — |
| Q4 2025 | Nov 14, 2025 | $0.13 | — |
Based on last 3 quarters of dataView full earnings history →
LNAI Peer Comparison
Lunai Bioworks Inc. (LNAI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 TWST | 5.45B | 87.56 | -67.35 | 20.32% | -19.85% | -17.46% | 0.29 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare LNAI vs Peers
Lunai Bioworks Inc. (LNAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LNAI Income Statement
Lunai Bioworks Inc. (LNAI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 20.94K |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 391.42K | 0 | 0 | 0 | 129.09K | 96.48K |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | -391.42K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -129.09K▲ 0% | -75.54K▲ 0% |
Gross Margin % | - | - | - | - | - | -360.71% |
Gross Profit Growth % | - | 100% | - | - | - | - |
Operating Expenses | 23.01M | 116.08M | 38.56M | 81.64M | 18.42M | 9.77M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 7.47M | 14.33M | 15.32M | 24.56M | 17.88M | 9.6M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 15.54M | 8.37M | 4.17M | 2.71M | 537.43K | 166.45K |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 0 | 93.38M | 19.07M | 54.37M | 0 | 0 |
Operating Income | -23.4M▲ 0% | -116.08M▼ 396.0% | -38.56M▲ 66.8% | -81.64M▼ 111.7% | -18.55M▲ 77.3% | -9.84M▲ 0% |
Operating Margin % | - | - | - | - | - | -46991.97% |
Operating Income Growth % | - | -396.03% | 66.78% | -111.74% | 77.28% | - |
EBITDA | -23.01M | -115.96M | -38.44M | -81.52M | -18.42M | -9.74M |
EBITDA Margin % | - | - | - | - | - | -46531.27% |
EBITDA Growth % | - | -403.93% | 66.85% | -112.05% | 77.41% | 91.39% |
D&A (Non-Cash Add-back) | 391.42K | 123.59K | 113.5K | 121.86K | 129.09K | 96.48K |
EBIT | -26.47M | -113.06M | -38.98M | -85.99M | -177.28M | -127.68M |
Net Interest Income | -366.43K | -250.8K | -706.96K | -2.43M | -609.34K | -599.34K |
Interest Income | 13.18K | 122.04K | 0 | 0 | 116.35K | 6.93K |
Interest Expense | 379.61K | 372.84K | 706.96K | 2.43M | 725.68K | 606.27K |
Other Income/Expense | -3.45M | 2.65M | -1.13M | -6.79M | -159.46M | -118.44M |
Pretax Income | -26.85M▲ 0% | -113.43M▼ 322.5% | -39.68M▲ 65.0% | -88.43M▼ 122.8% | -178.01M▼ 101.3% | -128.28M▲ 0% |
Pretax Margin % | - | - | - | - | - | -612568.11% |
Income Tax | -125.28K | 34 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.47% | -0% | 0% | 0% | 0% | 0% |
Net Income | -26.72M▲ 0% | -113.43M▼ 324.5% | -39.68M▲ 65.0% | -88.43M▼ 122.8% | -178.01M▼ 101.3% | -128.28M▲ 0% |
Net Margin % | - | - | - | - | - | -612568.11% |
Net Income Growth % | - | -324.47% | 65.02% | -122.82% | -101.31% | -26.77% |
Net Income (Continuing) | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M | -128.28M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -45.36▲ 0% | -172.80▼ 281.0% | -56.80▲ 67.1% | -72.80▼ 28.2% | -86.24▼ 18.5% | -41.06▲ 0% |
EPS Growth % | - | -280.95% | 67.13% | -28.17% | -18.46% | -8.32% |
EPS (Basic) | -45.36 | -172.80 | -56.80 | -72.80 | -86.24 | - |
Diluted Shares Outstanding | 589.59K | 656.6K | 703.32K | 1.22M | 2.06M | 3.12M |
Basic Shares Outstanding | 589.59K | 656.6K | 703.32K | 1.22M | 2.06M | 3.12M |
Dividend Payout Ratio | - | - | - | - | - | - |
LNAI Balance Sheet
Lunai Bioworks Inc. (LNAI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 20.9M | 9.57M | 2.57M | 2M | 1.05M | 3.73M |
Cash & Short-Term Investments | 20.66M | 9.17M | 1.87M | 220.47K | 480.55K | 3.16M |
Cash Only | 20.66M | 9.17M | 1.87M | 220.47K | 92.7K | 3.16M |
Short-Term Investments | 0 | 0 | 0 | 0 | 387.85K | 0 |
Accounts Receivable | 1.64K | 0 | 0 | 1.11M | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 393K | 690.92K | 668.93K | 566.08K | 577.38K |
Total Non-Current Assets | 168.71M | 75.07M | 55.74M | 161.13M | 7.18M | 6.13M |
Property, Plant & Equipment | 2.16M | 1.74M | 1.42M | 1.75M | 1.06M | 12.96K |
Fixed Asset Turnover | - | - | - | - | - | 0.08x |
Goodwill | 11.64M | 11.64M | 11.64M | 159.33M | 5.96M | 5.96M |
Intangible Assets | 154.89M | 61.62M | 42.65M | 30.04K | 165.99K | 119.11K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 20.98K | 68.64K | 21.74K | 19.85K | 0 | 32.82K |
Total Assets | 189.61M▲ 0% | 84.63M▼ 55.4% | 58.3M▼ 31.1% | 163.13M▲ 179.8% | 8.23M▼ 95.0% | 9.86M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x |
Asset Growth % | - | -55.36% | -31.11% | 179.81% | -94.95% | -374.88% |
Total Current Liabilities | 1.89M | 6.45M | 11.02M | 30.31M | 29.16M | 19.28M |
Accounts Payable | 320.56K | 1.4M | 5.3M | 9.45M | 12.56M | 12.68M |
Days Payables Outstanding | 298.93 | - | - | - | 35.5K | 46.97K |
Short-Term Debt | 353.01K | 1.2M | 4.62M | 2.45M | 9.44M | 991.66K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.21M | 2.56M | 184.73K | 12.61M | 1.01M | 414.63K |
Current Ratio | 11.08x | 1.48x | 0.23x | 0.07x | 0.04x | 0.19x |
Quick Ratio | 11.08x | 1.48x | 0.23x | 0.07x | 0.04x | 0.19x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 13.06M | 5.56M | 775.59K | 842.39K | 424.55K | 131.32K |
Long-Term Debt | 5.78M | 4.58M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 1.24M | 985.7K | 775.59K | 842.39K | 424.55K | 1.05M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6.04M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.94M | 12.01M | 11.8M | 31.15M | 29.58M | 19.41M |
Total Debt | 7.37M | 7.02M | 5.59M | 3.79M | 10.17M | 1.41M |
Net Debt | -13.29M | -2.16M | 3.72M | 3.57M | 10.08M | -1.74M |
Debt / Equity | 0.04x | 0.10x | 0.12x | 0.03x | - | -0.15x |
Debt / EBITDA | - | - | - | - | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | 0.18x |
Interest Coverage | -69.73x | -303.24x | -55.13x | -35.32x | -244.30x | -210.59x |
Total Equity | 174.66M▲ 0% | 72.62M▼ 58.4% | 46.5M▼ 36.0% | 131.98M▲ 183.8% | -21.35M▼ 116.2% | -9.55M▲ 0% |
Equity Growth % | - | -58.42% | -35.96% | 183.81% | -116.18% | -456.79% |
Book Value per Share | 296.24 | 110.60 | 66.12 | 108.28 | -10.35 | -3.06 |
Total Shareholders' Equity | 174.66M | 72.62M | 46.5M | 131.98M | -21.35M | -9.55M |
Common Stock | 5.22K | 5.3K | 6.37K | 15.85K | 17.74K | 3.58K |
Retained Earnings | -90.91M | -204.35M | -244.03M | -332.46M | -510.46M | -512.01M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -10.83K | -30.44K | -29.88K | -170.85K | 10.81M | -155.7K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
LNAI Cash Flow Statement
Lunai Bioworks Inc. (LNAI) cash flow — operating, investing & free cash flow history
| Metric | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -20.61M | -15.73M | -11.77M | -10.97M | -7.87M | -5.26M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | 23.67% | 25.16% | 6.82% | 28.23% | 147.17% |
Net Income | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M | -128.28M |
Depreciation & Amortization | 391.42K | 123.59K | 113.5K | 121.86K | 129.09K | 105.11K |
Stock-Based Compensation | 0 | 5.49M | 3.54M | 4.67M | 3.31M | 1.38M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.79M | 90.67M | 19.96M | 63.85M | 160.83M | 118.38M |
Working Capital Changes | 932.13K | 1.42M | 4.31M | 8.81M | 5.86M | 3.29M |
Change in Receivables | 342 | 1.59K | 46 | -1.11M | 1.15M | 96.66K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -272.32K | 1.08M | 3.89M | 4.06M | 3.11M | 2.25M |
Cash from Investing | -48.89K | -5.16K | -29.77K | -1.26M | -500K | 1.51M |
Capital Expenditures | -48.89K | -5.16K | -29.77K | -70.43K | 0 | -1.24K |
CapEx % of Revenue | - | - | - | - | - | 5.91% |
Acquisitions | 0 | 0 | 0 | -1.19M | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 32.6M | 4.25M | 4.52M | 10.52M | 8.38M | 6.18M |
Debt Issued (Net) | -546.65K | -560.85K | -1.12M | 8.05M | 6.98M | 1.2M |
Equity Issued (Net) | 31.93M | 4.68M | 4.01M | 3M | 2.38M | 5.25M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.22M | 134.91K | 503.23K | -528.21K | -971.23K | -271.64K |
Net Change in Cash | 11.97M▲ 0% | -11.49M▼ 196.0% | -7.3M▲ 36.5% | -1.65M▲ 77.3% | -127.77K▲ 92.3% | 2.23M▲ 0% |
Free Cash Flow | -20.66M▲ 0% | -15.74M▲ 23.8% | -11.8M▲ 25.0% | -11.04M▲ 6.5% | -7.87M▲ 28.7% | -5.26M▲ 0% |
FCF Margin % | - | - | - | - | - | -25114.87% |
FCF Growth % | - | 23.82% | 24.99% | 6.46% | 28.68% | 38.13% |
FCF per Share | -35.04 | -23.97 | -16.78 | -9.06 | -3.82 | -1.68 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.14x | 0.30x | 0.12x | 0.04x | 0.04x |
Interest Paid | 0 | 79.72K | 352.33K | 20.13K | 24.55K | 17.12K |
Taxes Paid | 0 | 34 | 0 | 0 | 0 | 0 |
LNAI Key Ratios
Lunai Bioworks Inc. (LNAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | -91.74% | -66.63% | -99.09% | -321.81% | 892.52% |
Return on Invested Capital (ROIC) | -75.11% | -47.92% | -65.92% | -22.39% | 66.2% |
Gross Margin | - | - | - | - | -360.71% |
Net Margin | - | - | - | - | -612568.11% |
Debt / Equity | 0.10x | 0.12x | 0.03x | - | -0.15x |
Interest Coverage | -303.24x | -55.13x | -35.32x | -244.30x | -210.59x |
FCF Conversion | 0.14x | 0.30x | 0.12x | 0.04x | 0.04x |
Related:LNAI Dividend History·LNAI Revenue History·LNAI Price History·LNAI P/E History·LNAI Financial Ratios·LNAI Institutional Holders
LNAI Frequently Asked Questions
Lunai Bioworks Inc. (LNAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lunai Bioworks Inc. (LNAI) reported $0.0M in revenue for fiscal year 2024.
Lunai Bioworks Inc. (LNAI) grew revenue by 0.0% over the past year. Growth has been modest.
Lunai Bioworks Inc. (LNAI) reported a net loss of $128.3M for fiscal year 2024.
Dividend & Returns
Lunai Bioworks Inc. (LNAI) has a return on equity (ROE) of -321.8%. Negative ROE indicates the company is unprofitable.
Lunai Bioworks Inc. (LNAI) had negative free cash flow of $5.3M in fiscal year 2024, likely due to heavy capital investments.